Skip to main content
 

Letters We've Submitted

CSC Comment Letter on the MassHealth Section 1115 Demonstration Amendment Request (October 2017)

CSC Comment Letter to Duke on the Framework for Regulatory Use of Real-World Evidence (October 2017)

Friends of CPI Comment Letter to E&C Committee on 340B Drug Discount Program (September 2017)

CSC Comments on the 340B Drug Discount Program within the CMS Proposed HOPPS and ASC Payment System Changes for 2018 (September 2017)

CSC Comments on ICER Background and Scope Document on Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value (August 2017)

CSC Comments on Docket No. FDA-2017-N-2732 for July 13, 2017 Oncologic Drugs Advisory Committee Meeting on Biologics License Applications 761028 and 761074 (July 2017)

CSC Comments on the Proposed Office of Patient Affairs (June 2017)

CSC Comment Letter on ISPOR Value Assessment Frameworks (May 2017)

CSC Response to President Trump's FY18 Budget Proposal (May 2017)

CSC Letter to Senate Leadership on AHCA (May 2017)

CSC Comment Letter on Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products (April 2017)

CSC Comment Letter to ICER on the Patient Engagement Guide (April 2017)

CSC Position Letter on Step Therapy (March 2017)

CSC's Comment Letter to ICER on the Value Assessment Framework Update (March 2017)

CSC’s Comment Letter to ICER on the Background and Scope Document on Poly ADP-ribose polymerase (PARP) Inhibitors for Ovarian Cancer (Long Version - March 2017)

CSC’s Comment Letter to ICER on the Background and Scope Document on Poly ADP-ribose polymerase (PARP) Inhibitors for Ovarian Cancer (Short Version - March 2017)

Friends of CPI Letter to CDER on Psychosocial Distress Screening in the Cancer Care Continuum (March 2017)

CSC Comment Letter to ICER on Lung Cancer Evidence Report Framework (September 2016)

CSC Comment Letter to ICER on Value Assessment Framework (September 2016)

CSC Comment Letter on PDUFA VI Goals Letter (August 2016)

CSC Comment Letter on MACRA Proposed Rule (June 2016)

CSC Comment Letter on Medicare Part B Proposed Rule (May 2016)

CSC Comment Letter to ICER on Assessment of Treatment Options for Multiple Myeloma (April 2016)

CSC Comments on Payment and Benefit Parameters (December 2015)

CSC Comment Letter to CDER on Psychosocial Distress Screening in Clinical Trials  (December 2015)

Friends of CPI Letter to HHS on Incorporating Psychosocial Oncology Care at the NIH and FDA (December 2015)

CSC Comment Letter to NCCN Evidence Blocks (December 2015)

CSC Comments to CMS and HHS Regarding MACRA (November 2015)

CSC Comments on Revisions to the Physician Fee Schedule (September 2015)

CSC Comments on Prescription Drug Fee User Act (PDUFA) (August 2015)

CSC Letter to National Government Services Medical Policy Unit (August 2015)

CSC's Response to ASCO Value Framework (August 2015)

CSC Comment Letter to Iowa DURC on Prior Authorization Restrictions(July 2015)

CSC Comments on the 21st Century Cures Act (July 2015)

CSC Comments on Ways to Improve Outcomes for Medicare Patients with Chronic Conditions (June 2015)

CSC Letter of Support for USPSTF Early Screening for Depression

CSC Comments on the Innovation for Healthier Americans Report (February 2015)

CSC Comments Regarding Cancer Care Payment Reform Act of 2015 (January 2015)

CSC Comments on Proposal Regarding Transparency for Incentive Payments (January 2015)

CSC Comments on FDA Activities for Patient Participation in Medical Product Discussions (December 2014)

CSC CEO Kim Thiboldeaux on the importance of patient perceptions of value in cancer care (Huffington Post- July 2014)

CSC Concerns with Proposed Rule Changes to Medicare Part D’s 6 Protected Classes (March 2014)

CSC Letter to House in Support of FDA Safety Over Sequestration Act (September 2013)

CSC Letter to Senate in Support of FDA Safety Over Sequestration Act (September 2013)

CSC Comments on Addressing the Drug Shortage in PDUFA (April 2012)